Lixte Biotechnology Holdings Q1 2025 10-Q Filing
Ticker: LIXT · Form: 10-Q · Filed: May 12, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, pharmaceuticals, financials
Related Tickers: LIXT
TL;DR
LIXT filed Q1 2025 10-Q. Financials and stock details updated.
AI Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed its quarterly report for the period ending March 31, 2025. The company, previously known as SRKP 7 INC, is involved in the pharmaceutical preparations industry. Key financial data and stock information are detailed within the filing.
Why It Matters
This filing provides investors with an update on Lixte Biotechnology's financial health and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry higher risks due to the nature of drug development and regulatory hurdles.
Key Numbers
- 0.0001 — Par Value Per Share (For Common Stock and Warrants to Purchase Common Stock)
- 1231 — Fiscal Year End (Indicates the company's annual reporting cycle)
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer of the 10-Q
- SRKP 7 INC (company) — Former name of LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
The company is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
What was the reporting period for this 10-Q filing?
The Conformed Period of Report was March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was made on May 12, 2025.
Did LIXTE BIOTECHNOLOGY HOLDINGS, INC. have a previous name?
Yes, the company was formerly known as SRKP 7 INC, with a name change date of August 3, 2005.
What is the par value for LIXTE's common stock and warrants?
The par value for LIXTE:CommonStockParValue0.0001PerShareMember and LIXTE:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember is $0.0001 per share.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).